Breaking Business News | Breaking business news AM | Breaking Business News PM

Moderna’s stock extends rally as experts look to the coming Phase 3 study of the coronavirus vaccine candidate

15 Jul 2020

Shares of Moderna Inc. rallied 10% in trading on Wednesday morning, the day after the drugmaker shared that its COVID-19 vaccine candidate produced neutralizing antibodies — thought to be a key benchmark for an effective coronavirus vaccine — in all 45 participants in a Phase 1 clinical trial.


Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.

Download